Effects of a hybrid recombinant human alpha interferon (A/D) on in vitro cytotoxicity and in vivo localization of monoclonal antibody L6-cytosine deaminase conjugate in a colon cancer model

Cancer Biotherapy and Radiopharmaceuticals

Volumn 13, Issue 1, 1998, Pages 33-42

  O'Boyle, Kevin P ^a   Senter, Peter D ^b   Bhargava, Kuldeep ^b   Chun, Sam ^b   Anthony, Gillian ^b   Markowitz, Adeline L ^b   Wadler, Scott ^b  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b NONE

Author keywords

5 fluorouracil; Colon cancer; Cytosine deaminase; Cytotoxicity; Localization; Monoclonal antibody

Indexed keywords

CYTOSINE DEAMINASE; FLUCYTOSINE; FLUOROURACIL; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY L 6; RECOMBINANT ALPHA INTERFERON A; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; COLON CARCINOMA; CYTOPATHOGENIC EFFECT; DRUG LIVER LEVEL; DRUG POTENTIATION; DRUG UPTAKE; GENETIC RECOMBINATION; HUMAN; HUMAN CELL; INTRAVENOUS DRUG ADMINISTRATION; LIVER CLEARANCE; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PLASMA CLEARANCE; PRIORITY JOURNAL;

EID: 0031939754     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.1998.13.33     Document Type: Article

References (22)

1. Cohen A, Minsky BD, and Schilsky. Colon cancer. Cancer: Principles and Practice of Oncology, Fourth Edition, edited by Vincent T. DeVita, Jr., Samuel Hellman, Steven A. Rosenberg. J.B. Lippincott Co., Philadelphia 1993, p. 929-977.
2. Petrelli N, Douglass HO Jr, Herrara L, Russel D, Stablein DM, Bruckner HW, et al. The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomized phase III trial. J Clin Oncol 1989;7:1419-1426.
3. Doroshaw JH, Multhauf P, Leong L, Margolin K, Litchfield T, Akman S, et al. Prospective randomized comparison of flurouracil versus fluorouracil and high dose continuous infusion leucovorin calcium for the treatment of advanced measurable colorectal carcinoma in patients previously unexposed to chemotherapy. J Clin Oncol 1990;8:491-501.
4. O'Dwyer PJ, Paul AR, Walczak J, Weiner LM, Litwin S, and Comis RL, et al. Phase II study of biochemical modulation of fluorouracil by low dose PALA in patients with colorectal carcinoma. J Clin Oncol 1990; 8:1497-1503.
5. Wadler S, Wersto R, Weinberg V, Thompson D, and Schwartz EL. Interaction of flurouracil and interferon in human colon cancer cell lines: Cytotoxic and cytokinetic effects. Cancer Res 1990,50:5735-5739.
6. Wadler S, and Wiernik PH. Clinical update on the role of fluorouracil and recombinant alpha-2a in the treatment of colorectal carcinoma. Sem in Oncol 1990;9:16-21 (Suppl 1).
7. Hellstrom I, Garrigues U, Lavie E, and Hellstrom KE. Antibody mediated killing of human tumor cells by attached effector cells. Cancer Res 1988;48:624-627.
8. Goodman GE, Hellstrom I, Brodzinsky L, Nicaise C, Kulander B, Hummel D, and Hellstrom KE. Phase I trial of murine monoclonal antibody L6 in breast, colon, ovarian, and lung cancer. J Clin Oncol 1990,8:1083-1092
9. Senter PD, Wallace PM, Svensson HP, Vrudhula VM, Kerr DE, Hellstrom I and Hellstrom KE. Generation of cytotoxic agents by targeted enzymes. Bioconjugate Chem 1993;4:3-9.
10. Bagshawe KD, Springer CJ, Searle F. A cytotoxic agent can be generated selectively at cancer sites. Br J Cancer 1988;58:700-703.
11. Senter PD, Saulnier MG, Schreiber GJ, Hirshberg DL, Brown JP, Hellstrom I, and Hellstrom KE. Antitumor effects of antibody-alkaline phosphatase conjugates in combination with etoposide phosphate. Proc Natl Acad Sci USA 1988;85:4842-4846.
12. Svensson HP, Kadow JF, Vrudhulka VM, Wallace PM, and Senter PD. Monoclonal antibody-β-lactamase conjugates for the activation of a cephalosporin mustard prodrug. Bioconjugate Chem 1992;3:176-181.
13. Svensson HP, Vrudhula VM, Emswiler JE, MacMaster JF, Cosand WL, Senter PD, and Wallace PM. In vitro and in vivo activities of a doxorubicin prodrug in combination with monoclonal antibody β-lactamase conjugates Cancer Res 1995,55:2357-2365.
14. Kerr DE, Schreiber GJ, Vrudhula VM, Svensson H, Hellstrom J, Hellstrom KE, and Senter PD. Regressions and cures of melanoma xenografts following treatment with monoclonal antibody β-lactamase conjugates in combination with anticancer prodrugs. Cancer Res 1995; 55:3558-3563.
15. Austin EA, and Huber BE. A first step in the development of gene therapy for colorectal carcinoma: cloning, sequencing, and expression of E. coli cytosine deaminase. Mol Pharmacol 1993;43:380-387
16. Huber BE, Austin EA, Good SS, Knick VC, Tibbels S, and Richards CA. In vivo antitumor activity of 5-fluorocytosine on human colorectal carcinoma cells genetically modified to express cytosine deaminase. Cancer Res 1993;53:4619-4626.
17. Senter PD, Su PCD, Katsuragi T, Sakai T, Cosand WL, Hellstrom I, and Hellstrom KE. Generation of 5-fluorouracil from 5-fuorocytosine by monoclonal antibody-cytosine deaminase conjugates. Bioconjugate Chem 1991; 2:447-451.
18. Wallace PM, MacMaster JF, Smith VF, Kerr DE, Senter PD, and Cosand WL. Intratumoral generation of 5-fluorouracil mediated by an antibody-cytosine deaminase conjugate in combination with 5-fluorocytosine. Cancer Res 1994;54:2719-2723.
19. Hellstrom KE, Yelton DE, Fell PH, Beaton D, Gayle M, MacLean M, Kahn M, and Hellstrom I. Epitope mapping and use of anti-idiotypic antibodies to the L6 monoclonal anticarcinoma antibody. Cancer Res 1990; 50:2449-2454.
20. Kramer MJ, Dennin R, Kramer C, Jones G, Connell E, Rolon N, Gruarin A, Kale R, and Trown PW. Cell and virus sensitivity studies with recombinant human alpha interferons. J Interferon Res 1983;2:425-435.
21. Edmondson JM, Armstrong LS, Martinez AO. A rapid and simple MTT-based spectrophotometric assay for determining drug sensitivity in monolayer cultures. J Tissue Culture Methods 1988;11:15-17.
22. O'Boyle KP, Mattes MJ, Sigurdson ER, Sutanto-Ward E, Divgi CR, Welt S, and Wright KE. Localization of complement-fixing cytotoxic monoclonal antibodies to subcutaneous tumors and liver metastases in a syngeneic immunocompetent rat colon carcinoma model. J Immunotherapy 1994;15.175-184.